Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens.
Fiche publication
Date publication
juin 2017
Journal
Journal of vascular and interventional radiology : JVIR
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIOT Olivier, Pr THIEFIN Gérard
Tous les auteurs :
D'inca H, Piot O, Diebold MD, Piardi T, Marcus C, Burde F, Sommacale D, Manfait M, Thiéfin G
Lien Pubmed
Résumé
This study evaluated the midterm delivery of doxorubicin in liver specimens from patients (N = 4) with hepatocellular carcinoma treated with drug-eluting embolic (DEE) transarterial chemoembolization. The patients had surgical resection 57, 79, 80 and 105 days after doxorubicin DEE chemoembolization. Doxorubicin concentrations inside embolic particles and in surrounding tissues were assessed by infrared microspectroscopy and microspectrofluorimetry, respectively. Embolic particles still contained doxorubicin and provided sustained drug delivery within targeted tissues 80 days after chemoembolization. Doxorubicin was undetectable after 105 days. In addition, aggregation of embolic particles inside vessel lumina was associated with slower doxorubicin elution and higher tissue concentrations when the number of aggregated embolic particles increased.
Mots clés
Antibiotics, Antineoplastic, administration & dosage, Carcinoma, Hepatocellular, metabolism, Chemoembolization, Therapeutic, methods, Combined Modality Therapy, Doxorubicin, administration & dosage, Hepatectomy, Humans, Liver Neoplasms, metabolism, Male, Middle Aged, Spectroscopy, Fourier Transform Infrared, Treatment Outcome
Référence
J Vasc Interv Radiol. 2017 Jun;28(6):804-810